相关临床试验
1411
139 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1841
Unknown
3
0.2%
已完成
791
56.1%
Enrolling By Invitation
11
0.8%
尚未招募
62
4.4%
No Longer Available
1
0.1%
终止
132
9.4%
招募中
181
12.8%
暂停
11
0.8%
Approved For Marketing
1
0.1%
撤回
152
10.8%
进行中（未招募）
66
4.7%
暂无批准数据
- NYU Langone Health and Dana-Farber Cancer Institute have co-developed Solavia Decision Suite, an oncology clinical decision support platform that launched internally on June 30 and is now commercially available. - The platform integrates directly into the electronic health record, providing oncologists with seamless access to the latest evidence, biomarkers, guidelines, and therapeutic options at the point of care. - The collaboration emerged after Philips sunset its oncology pathways business, prompting the two institutions to build a more robust, scalable, and workflow-integrated solution rather than adopt an existing vendor product. - Solavia is designed to strengthen care standardization, reduce unnecessary variation, and support precise, evidence-based treatment decisions across multidisciplinary cancer care teams.
- Patient-authored portal messages increased 153% between 2020 and 2025, rising from 0.99 to 2.5 messages per patient per year, according to the largest-ever analysis of Epic electronic health records published in JAMA. - The study analyzed over 8 billion patient-provider interactions across 2,067 hospitals and 47,100 clinics, finding that digital communication supplements rather than replaces in-person care, with office visits rising 17% over the same period. - Researchers warn that the growing digital workload may contribute to provider burnout and requires health systems to plan for increased messaging volume, staffing adjustments, and AI support tools. - Thirty percent of active Epic patients—42 million Americans—sent a portal message to their clinician during the first quarter of 2025, signaling a structural shift in how patients and providers communicate.
- A national study of 720,348 referred patients found that 48% never started the transplant evaluation process, and only 19% ultimately reached the waitlist. - Unmarried, older, Spanish-speaking, rural, and lower-income patients were disproportionately likely to drop out before completing evaluation. - Smaller transplant centers and programs in the southern United States showed lower rates of patient progression to the waitlist. - Researchers call for better patient education, transportation support, and navigation assistance to reduce barriers to kidney transplantation.
- Judy and Stewart Colton's $15 million gift will be shared across NYU Langone, Yale University, and Tel Aviv University to advance collaborative autoimmune disease research. - The Colton Consortium enables real-time sharing of ideas, technologies, patient cohorts, and expertise to predict optimal treatments for individual patients. - NYU Langone's Colton Center pursues translational research integrating clinical care, immunology, genetics, microbiome science, and data-driven discovery across multiple immune-mediated diseases. - Prior Colton-funded work has already yielded a successful research partnership with biopharmaceutical company argenx, demonstrating the program's impact on drug development.
- A pioneering phase 1 clinical trial used dual CAR T cell therapy (CD19 and BCMA-targeted) to successfully desensitize three highly sensitized end-stage kidney disease patients, enabling previously impossible kidney transplants. - The study, published in The New England Journal of Medicine, marks the first demonstration that CAR T cells can be used outside oncology to eliminate antidonor antibodies and reset the immune system. - Neither of the first two treated patients developed severe cytokine release syndrome or neurotoxicity, and healthy B cell populations gradually recovered after temporary depletion. - Among the roughly 5,000 highly sensitized Americans on the kidney waitlist, patients with cPRA scores of 99.9% or higher average only one donor offer per decade, highlighting the transformative potential of this approach.
- New Phase 3 post hoc analyses demonstrate that centanafadine, a first-in-class NDSRI, improves executive function and emotional dysregulation in adults with ADHD beyond core symptoms. - The study included 744 adults across two dose groups (200mg and 400mg) and showed statistically significant improvements in time management, planning, and emotional control at Week 6. - Centanafadine is currently under FDA Priority Review with a target action date of July 24, 2026, potentially addressing unmet needs in adult ADHD treatment. - The drug demonstrated a favorable safety profile with low abuse potential, with the most common adverse events being decreased appetite and headache.
- Twelve years after the Ice Bucket Challenge raised more than $1 billion for ALS research, artificial intelligence is now powering early detection models and voice-cloning tools to improve patient care and quality of life. - ALS remains incurable and fatal, with over 5,000 Americans diagnosed annually and an estimated 30,000 to 35,000 currently living with the disease, according to the CDC. - New gene-targeted therapies have raised hopes of making ALS a livable or chronic condition, with researchers describing the progress as "right at our fingertips." - The Pete Frates Family Foundation and Boston-based AI provider NWN are partnering to accelerate ALS research and preserve patients' voices through advanced technology.
- Bracco Imaging and NYU Langone Health signed a multi-year Master Research Agreement to accelerate development of advanced imaging technologies including MRI, CT, ultrasound and PET/CT. - The collaboration will focus on Photon-Counting Computed Tomography, targeted ultrasound, and artificial intelligence-enabled PET/CT and MRI image analysis to support precision medicine. - The partnership aims to enhance diagnostic performance, streamline clinical workflows, and facilitate translation of scientific discoveries into real-world healthcare applications. - NYU Langone Health has been ranked No. 1 out of 118 comprehensive academic medical centers for four consecutive years by Vizient, Inc.
- BioLineRx is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma treatment by the end of March 2026, marking the first-in-human study of this novel DNA damage response inhibitor. - The company received USPTO patent allowance for GLIX1 covering 90% of all cancers where cytidine deaminase is not over-expressed, extending patent protection until 2040 with possible five-year extension. - BioLineRx reported $1.2 million in revenues for 2025 from APHEXDA royalties and maintains $20.9 million cash runway extending into the first half of 2027. - The CheMo4METPANC Phase 2b trial of motixafortide in metastatic pancreatic cancer has accelerated enrollment, with interim analysis expected in 2026.
- NeOnc Technologies will host an investor conference call on March 4, 2026, to present initial Phase 1 dose-escalation data from the NEO212-01 clinical trial evaluating their bioconjugated temozolomide platform for CNS malignancies. - The presentation will include safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps from the Phase 1/2 clinical trial. - The company's NEO212 therapeutic is part of a proprietary drug development platform designed to overcome blood-brain barrier challenges and is currently advancing under FDA Fast-Track status. - Distinguished neuro-oncology experts from Duke University and NYU Langone Health will participate as independent Scientific Advisory Board members in the data presentation.
